Sami Anttila, Ari Illi, Olli Kampman, Kari M Mattila, Terho Lehtimäki, Esa Leinonen
{"title":"NOTCH4与儿茶酚- o -甲基转移酶基因型在典型抗精神病药反应不良的精神分裂症患者中的相互作用","authors":"Sami Anttila, Ari Illi, Olli Kampman, Kari M Mattila, Terho Lehtimäki, Esa Leinonen","doi":"10.1097/00008571-200405000-00005","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>In this study we attempted to show that the interaction between NOTCH4 and catechol-O-methyltransferase (COMT) polymorphism predicts the response to typical neuroleptics in schizophrenia. Our sample consisted of 94 Finnish patients with DSM-IV schizophrenia and 98 controls.</p><p><strong>Methods: </strong>Several studies have connected COMT and NOTCH4 genes to schizophrenia. We have previously shown that COMT polymorphism is significantly associated with treatment response in schizophrenia. NOTCH4 SNP2 polymorphism has been associated with age of onset in schizophrenia, but there is also a trend that this polymorphism may predict response to typical neuroleptics. In the present sample, there is a strong gene-gene interaction between these genes (P = 0.003) and they have additive effect in treatment response.</p><p><strong>Results: </strong>Patients carrying both NOTCH4 C/C genotype and COMT low/low genotype, had more than ten times higher risk of being a non-responder than responder to treatment with typical neuroleptics [OR = 10.25 (95% CI 2.21-47.53), P < 0.001]. This combination of genotypes is also more common in patients considered non-responders than in controls [OR = 3.00 (95% CI 1.33-6.76), P = 0.007].</p><p><strong>Conclusion: </strong>Our results suggest that an interaction between COMT and NOTCH4 genotypes may predict the treatment response to typical neuroleptics in patients with schizophrenia.</p>","PeriodicalId":19917,"journal":{"name":"Pharmacogenetics","volume":"14 5","pages":"303-7"},"PeriodicalIF":0.0000,"publicationDate":"2004-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00008571-200405000-00005","citationCount":"46","resultStr":"{\"title\":\"Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics.\",\"authors\":\"Sami Anttila, Ari Illi, Olli Kampman, Kari M Mattila, Terho Lehtimäki, Esa Leinonen\",\"doi\":\"10.1097/00008571-200405000-00005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>In this study we attempted to show that the interaction between NOTCH4 and catechol-O-methyltransferase (COMT) polymorphism predicts the response to typical neuroleptics in schizophrenia. Our sample consisted of 94 Finnish patients with DSM-IV schizophrenia and 98 controls.</p><p><strong>Methods: </strong>Several studies have connected COMT and NOTCH4 genes to schizophrenia. We have previously shown that COMT polymorphism is significantly associated with treatment response in schizophrenia. NOTCH4 SNP2 polymorphism has been associated with age of onset in schizophrenia, but there is also a trend that this polymorphism may predict response to typical neuroleptics. In the present sample, there is a strong gene-gene interaction between these genes (P = 0.003) and they have additive effect in treatment response.</p><p><strong>Results: </strong>Patients carrying both NOTCH4 C/C genotype and COMT low/low genotype, had more than ten times higher risk of being a non-responder than responder to treatment with typical neuroleptics [OR = 10.25 (95% CI 2.21-47.53), P < 0.001]. This combination of genotypes is also more common in patients considered non-responders than in controls [OR = 3.00 (95% CI 1.33-6.76), P = 0.007].</p><p><strong>Conclusion: </strong>Our results suggest that an interaction between COMT and NOTCH4 genotypes may predict the treatment response to typical neuroleptics in patients with schizophrenia.</p>\",\"PeriodicalId\":19917,\"journal\":{\"name\":\"Pharmacogenetics\",\"volume\":\"14 5\",\"pages\":\"303-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2004-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1097/00008571-200405000-00005\",\"citationCount\":\"46\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacogenetics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/00008571-200405000-00005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenetics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/00008571-200405000-00005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 46
摘要
目的:在本研究中,我们试图证明NOTCH4和儿茶酚- o -甲基转移酶(COMT)多态性之间的相互作用预测精神分裂症患者对典型神经抑制剂的反应。我们的样本包括94名患有DSM-IV精神分裂症的芬兰患者和98名对照组。方法:多项研究将COMT和NOTCH4基因与精神分裂症联系起来。我们之前已经表明,COMT多态性与精神分裂症的治疗反应显著相关。NOTCH4 SNP2多态性与精神分裂症的发病年龄有关,但也有一种趋势,即这种多态性可能预测对典型抗精神病药物的反应。在本样本中,这些基因之间存在很强的基因-基因相互作用(P = 0.003),它们在治疗反应中具有加性效应。结果:携带NOTCH4 C/C基因型和COMT低/低基因型的患者对典型抗精神病药物治疗无反应的风险比有反应的风险高10倍以上[OR = 10.25 (95% CI 2.21-47.53), P < 0.001]。这种基因型组合在无反应患者中也比在对照组中更常见[OR = 3.00 (95% CI 1.33-6.76), P = 0.007]。结论:我们的研究结果表明,COMT和NOTCH4基因型之间的相互作用可能预测精神分裂症患者对典型抗精神病药的治疗反应。
Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics.
Objective: In this study we attempted to show that the interaction between NOTCH4 and catechol-O-methyltransferase (COMT) polymorphism predicts the response to typical neuroleptics in schizophrenia. Our sample consisted of 94 Finnish patients with DSM-IV schizophrenia and 98 controls.
Methods: Several studies have connected COMT and NOTCH4 genes to schizophrenia. We have previously shown that COMT polymorphism is significantly associated with treatment response in schizophrenia. NOTCH4 SNP2 polymorphism has been associated with age of onset in schizophrenia, but there is also a trend that this polymorphism may predict response to typical neuroleptics. In the present sample, there is a strong gene-gene interaction between these genes (P = 0.003) and they have additive effect in treatment response.
Results: Patients carrying both NOTCH4 C/C genotype and COMT low/low genotype, had more than ten times higher risk of being a non-responder than responder to treatment with typical neuroleptics [OR = 10.25 (95% CI 2.21-47.53), P < 0.001]. This combination of genotypes is also more common in patients considered non-responders than in controls [OR = 3.00 (95% CI 1.33-6.76), P = 0.007].
Conclusion: Our results suggest that an interaction between COMT and NOTCH4 genotypes may predict the treatment response to typical neuroleptics in patients with schizophrenia.